| Literature DB >> 27011211 |
Tian-tian Tian1, Jian-hong Zhao1, Jing Yang1, Cui-xin Qiang1, Zhi-rong Li1, Jing Chen2, Kai-yue Xu1, Qing-qing Ciu1, Ru-xin Li1.
Abstract
Clostridium difficile is a spore-forming, gram-positive, anaerobic bacillus that can cause C. difficile infection (CDI). However, only a few studies on the prevalence and antibiotic resistance of C. difficile in healthy individuals in China have been reported. We employed a spore enrichment culture to screen for C. difficile in the stool samples of 3699 healthy Chinese individuals who were divided into 4 groups: infants younger than 2 years of age and living at home with their parents; children aged 1 to 8 years of age and attending three different kindergarten schools; community-dwelling healthy adult aged 23-60 years old; and healthcare workers aged 28-80 years old. The C. difficile isolates were analyzed for the presence of toxin genes and typed by PCR ribotyping and multilocus sequence typing (MLST). The minimum inhibitory concentration of 8 antimicrobial agents was determined for all of the isolates using the agar dilution method. The intestinal carriage rate in the healthy children was 13.6% and ranged from 0% to 21% depending on age. The carriage rates in the 1654 community-dwelling healthy adults and 348 healthcare workers were 5.5% and 6.3%, respectively. Among the isolates, 226 were toxigenic (225 tcdA+/tcdB+ and 1 tcdA+/tcdB+ ctdA+/ctdB+). Twenty-four ribotypes were found, with the dominant type accounting for 29.7% of the isolates. The toxigenic isolates were typed into 27 MLST genotypes. All of the strains were susceptible to vancomycin, metronidazole, fidaxomicin, and rifaximin. High resistance to levofloxacin and ciprofloxacin at rates of 39.8% and 98.3%, respectively, were observed. ST37 isolates were more resistant to levofloxacin than the other STs. The PCR ribotypes and sequence types from the healthy populations were similar to those from the adult patients.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27011211 PMCID: PMC4807052 DOI: 10.1371/journal.pone.0151964
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Primers used in the present study.
| Analysis | Gene target | Primer name | Sequence (5'–3') | Amplicon size (bp) |
|---|---|---|---|---|
| 5-plex PCR | tcdA | tcdA-F3345 | GCATGATAAGGCAACTTCAGTGGTA | 629 |
| tcdA-R3969 | AGTTCCTCCTGCTCCATCAAATG | |||
| tcdB | tcdB-F5670 | CCAAARTGGAGTGTTACAAACAGGTG | 410 | |
| tcdB-R6079A | GCATTTCTCCATTCTCAGCAAAGTA | |||
| tcdB-R6079B | GCATTTCTCCGTTTTCAGCAAAGTA | |||
| cdtA | cdtA-F739A | GGGAAGCACTATATTAAAGCAGAAGC | 221 | |
| cdtA-F739B | GGGAAACATTATATTAAAGCAGAAGC | |||
| cdtA-R958 | CTGGGTTAGGATTATTTACTGGACCA | |||
| cdtB | cdtB-F617 | TTGACCCAAAGTTGATGTCTGATTG | 262 | |
| cdtB-R878 | CGGATCTCTTGCTTCAGTCTTTATAG | |||
| 16S rDNA | PS13 | GGAGGCAGCAGTGGGGAATA | 1062 | |
| PS14 | TGACGGGCGGTGTGTACAAG | |||
| PCR ribotyping | 16–23S rDNA | PRB | GTGCGGCTGGATCACCTCCT | |
| PRBas | CCCTGCACCCTTAATAACTTGACC | |||
| MLST | adk | adk1F | TTACTTGGACCTCCAGGTGC | 635 |
| adk1R | TTTCCACTTCCTAAGGCTGC | |||
| atpA | atpA1F | TGATGATTTAAGTAAACAAGCTG | 674 | |
| atpA1R | AATCATGAGTGAAGTCTTCTCC | |||
| dxr | dxr3F | GCTACTTTCCATTCTATCTG | 525 | |
| dxr4R | CCAACTCTTTGTGCTATAAA | |||
| glyA | glyA1F | ATAGCTGATGAGGTTGGAGC | 625 | |
| glyA1R | TTCTAGCCTTAGATTCTTCATC | |||
| recA | recA2F | CAGTAATGAAATTGGGAGAAGC | 705 | |
| recA2R | ATTCAGCTTGCTTAAATGGTG | |||
| sodA | sodA5F | CCAGTTGTCAATGTATTCATTTC | 585 | |
| sodA6R | ATAACTTCATTTGCTTTTACACC | |||
| tpi | tpi2F | ATGAGAAAACCTATAATTGCAG | 640 | |
| tpi2R | TTGAAGGTTTAACACTTCCACC |
Characteristics of infants aged 0–2 years with and without C. difficile.
| Characteristic | |||
|---|---|---|---|
| Sex, M/F | 6/3 | 18/9 | 1 |
| Median age in months (range) | 6 (1–18) | 5 (1–24) | 0.408 |
| Breast milk feeding | 8 | 25 | 1 |
| Food diversity at time of stool collection | 7 | 9 | 0.049 |
| Delivery route (vaginal/caesarean) | 2/7 | 15/12 | 0.128 |
a Comparisons between carriers and non-carriers of C. difficile were performed using Fisher’s exact test.
Asymptomatic intestinal C. difficile carriage rate (%) in healthy children in the 3 kindergartens(group B).
| Age (years) | 1–2 | 2–3 | 3–4 | 4–5 | 5–6 | 6–7 | 7–8 | Total |
|---|---|---|---|---|---|---|---|---|
| Kindergarten I | 0/3 (0) | 8/69 (11.6) | 51/288 (17.8) | 30/279 (10.8) | 35/247 (14.2) | 3/38 (7.9) | 0/7 (0) | 127/931 (13.6) |
| Kindergarten II | NS | NS | 29/144 (20.1) | 22/184 (12.0) | 26/247 (10.5) | 2/25 (8.0) | NS | 79/600 (13.1) |
| Kindergarten III | 0/5 (0) | 3/10 (30) | 3/27 (11.1) | 5/16 (31.2) | 3/24 (12.5) | 2/48 (4.2) | NS | 16/130 (12.3) |
| Total | 0/8 (0) | 11/79 (13.9) | 83/459 (18.0) | 57/479 (11.9) | 64/518 (12.4) | 7/111 (6.3) | 0/7 (0) | 222/1661 (13.4) |
Note: NS: no subjects
Fig 1Frequency of PRs among the 344 C. difficile isolates from healthy Chinese individuals.
Fig 2Abundance of STs (%) in the 3 study populations.
Data on the STs of C. difficile isolates from adult inpatients with diarrhea were obtained from a survey conducted in China in 2011.
Fig 3eBURST diagram of the 226 toxigenic C. difficile isolates from the healthy individuals.
(a) Population snapshot showing the clusters of linked sequence types (STs) and unlinked STs in the entire C. difficile MLST database. (b) Three new STs (286, 289, and 290) were identified in this study.
MICs of 8 antimicrobial agents for 344 C. difficile isolates determined by the agar dilution method.
| Antimicrobial agent | MIC breakpoint (mg/L) | MIC50 (mg/L) | MIC90 (mg/L) | Range (mg/L) | Resistance (%) |
|---|---|---|---|---|---|
| Vancomycin | > 2 | 0.25 | 0.5 | 0.03–1 | 0 |
| Metronidazole | ≥ 32 | 0.25 | 0.5 | 0.03–1 | 0 |
| Fidaxomicin | 0.06 | 0.125 | 0.0075–0.5 | ||
| Rifaximin | ≥ 4 | 0.015 | 0.015 | 0.0009–0.03 | 0 |
| Levofloxacin | ≥ 8 | 4 | 8 | 2–128 | 39.8 |
| Ciprofloxacin | ≥ 8 | 8 | 16 | 4–128 | 98.3 |
| Meropenem | ≥ 16 | 2 | 4 | 1–16 | 1.45 |
| Chloramphenicol | ≥ 32 | 8 | 16 | 2–64 | 2.0 |
a Breakpoint was not established for fidaxomicin.
MICs of 8 antimicrobial agents for toxigenic and non-toxigenic C. difficile isolates as determined by using agar dilution.
| Antimicrobial agent | ||||||||
|---|---|---|---|---|---|---|---|---|
| Range (mg/L) | MIC50 (mg/L) | MIC90 (mg/L) | Resistance (%) | Range (mg/L) | MIC50 (mg/L) | MIC90 (mg/L) | Resistance (%) | |
| Vancomycin | 0.03–1 | 0.25 | 0.5 | 0 | 0.03–1 | 0.25 | 0.5 | 0 |
| Metronidazole | 0.06–0.5 | 0.25 | 0.5 | 0 | 0.03–1 | 0.25 | 0.5 | 0 |
| Fidaxomicin | 0.0075–0.5 | 0.06 | 0.125 | 0 | 0.0075–0.5 | 0.06 | 0.125 | 0 |
| Rifaximin | 0.0009–0.25 | 0.015 | 0.015 | 0 | 0.0009–0.25 | 0.015 | 0.03 | 0 |
| Levofloxacin | 2–128 | 4 | 8 | 40.3 | 2–128 | 4 | 8 | 39.8 |
| Ciprofloxacin | 4–128 | 16 | 16 | 99.6 | 4–128 | 8 | 16 | 95.8 |
| Meropenem | 1–16 | 2 | 4 | 1.8 | 1–16 | 2 | 4 | 0.8 |
| Chloramphenicol | 2–64 | 8 | 16 | 3.5 | 4–64 | 8 | 16 | 0.8 |
a MICs between toxigenic and non-toxigenic C. difficile isolates were compared using Fisher’s exact test (P < 0.05).
Characteristics of the 226 toxigenic C. difficile strains: genotype and antimicrobial susceptibility.
| No.of isolates (%)(total n = 226) | ST | Vancomycin (% R) | Metronidazole (% R) | Fidaxomicin (%R) | Rifaximin (% R) | Levofloxacin (% R) | Ciprofloxacin (% R) | Meropenem (%R) | Chloramphenicol (% R) |
|---|---|---|---|---|---|---|---|---|---|
| 66 (29.2) | 54 | 0 | 0 | 0 | 0 | 39 | 100 | 0 | 3 |
| 58 (25.6) | 3 | 0 | 0 | 0 | 0 | 24 | 100 | 3.4 | 2 |
| 24 (10.6) | 35 | 0 | 0 | 0 | 0 | 50 | 100 | 0 | 17 |
| 22 (9.7) | 2 | 0 | 0 | 0 | 0 | 32 | 100 | 4.5 | 5 |
| 19 (8.4) | 37 | 0 | 0 | 0 | 0 | 84 | 100 | 0 | 5 |
| 6 (2.7) | 26 | 0 | 0 | 0 | 0 | 1/6 | 0 | 0 | 0 |
| 4 (1.8) | 8 | 0 | 0 | 0 | 0 | 0 | 4/4 | 0 | 0 |
| 4 (1.8) | 48 | 0 | 0 | 0 | 0 | 2/4 | 4/4 | 0 | 0 |
| 3 (1.3) | 139 | 0 | 0 | 0 | 0 | 3/3 | 3/3 | 0 | 0 |
| 2 (0.9) | 205 | 0 | 0 | 0 | 0 | 2/2 | 2/2 | 0 | 0 |
| 2 (0.9) | 99 | 0 | 0 | 0 | 0 | 0 | 2/2 | 0 | 0 |
| 1 (0.4) | 5 | 0 | 0 | 0 | 0 | 0 | 1/1 | 0 | 0 |
| 1 (0.4) | 15 | 0 | 0 | 0 | 0 | 1/1 | 1/1 | 0 | 0 |
| 1 (0.4) | 33 | 0 | 0 | 0 | 0 | 0 | 1/1 | 0 | 0 |
| 1 (0.4) | 39 | 0 | 0 | 0 | 0 | 1/1 | 1/1 | 0 | 0 |
| 1 (0.4) | 42 | 0 | 0 | 0 | 0 | 1/1 | 1/1 | 0 | 0 |
| 1 (0.4) | 51 | 0 | 0 | 0 | 0 | 1/1 | 1/1 | 0 | 0 |
| 1 (0.4) | 55 | 0 | 0 | 0 | 0 | 0 | 1/1 | 0 | 0 |
| 1 (0.4) | 69 | 0 | 0 | 0 | 0 | 1/1 | 1/1 | 0 | 0 |
| 1 (0.4) | 76 | 0 | 0 | 0 | 0 | 0 | 1/1 | 1/1 | 0 |
| 1 (0.4) | 81 | 0 | 0 | 0 | 0 | 1/1 | 1/1 | 0 | 0 |
| 1 (0.4) | 129 | 0 | 0 | 0 | 0 | 0 | 1/1 | 0 | 0 |
| 1 (0.4) | 150 | 0 | 0 | 0 | 0 | 1/1 | 1/1 | 0 | 0 |
| 1 (0.4) | 234 | 0 | 0 | 0 | 0 | 1/1 | 1/1 | 0 | 0 |
| 1 (0.4) | 286 | 0 | 0 | 0 | 0 | 0 | 1/1 | 0 | 0 |
| 1 (0.4) | 289 | 0 | 0 | 0 | 0 | 0 | 1/1 | 0 | 0 |
| 1 (0.4) | 290 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
a For ST54, ST3, ST35, ST2, and ST37, resistance is expressed as a %; for the remaining STs, the number of resistant isolates is shown.
b Resistance among the different STs was compared using Fisher’s exact test (vs. levofloxacin, P < 0.05)